Categories: Health

Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference

PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET

A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.

About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com   

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com 

GlobeNews Wire

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

3 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

7 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

7 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

7 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

7 hours ago